|Waleed Hassanein, MD|
Waleed Hassanein, M.D.: TransMedics Founder, President, and CEO
Waleed Hassanein, M.D., is president and CEO of TransMedics, Inc., a company he founded in August 1998. He brings more than fifteen years of experience in establishing and leading executive teams through the clinical development, market launch, and commercial rollout of the company’s breakthrough Organ Care System (OCS™) technology in Europe and the United States.
Under his leadership, TransMedics has established a new medical device market in organ preservation for transplantation. Creating this market has required the development of new reimbursement processes, regulatory approvals, and market dynamics. Today, TransMedics is recognized as the global market leader for ex-vivo physiologic organ preservation, optimization, and assessment of solid organs for transplantation. The TransMedics’ OCS™ Technology is well underway to become the new standard of care for solid organ preservation worldwide. It enables improved clinical outcomes and significantly expands the number of organs available for transplantation to meet the growing demand.
Dr. Hassanein is considered as an international expert in the field of ex-vivo machine perfusion for solid organ transplants, a field he pioneered over the past two decades. Dr. Hassanein is a frequent guest speaker in national and international symposiums on the future of organ preservation for transplantation.
Dr. Hassanein earned his M.D. at Georgetown University, where he also completed a two-year residency in general surgery. He then completed a three-year cardiac surgery research fellowship at the West Roxbury VA Medical Center and Brigham and Women’s Hospital in Boston. His research on ex-vivo heart perfusion for transplantation was recognized by the American Association for Thoracic Surgery in 1998.